Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trastuzumab rezetecan - Jiangsu HengRui Medicine

Drug Profile

Trastuzumab rezetecan - Jiangsu HengRui Medicine

Alternative Names: SHR-A1811

Latest Information Update: 03 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Developer Fudan University; Jiangsu Hengrui Medicine Co.; Suzhou Suncadia Biopharmaceuticals
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Cell death stimulants; DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer; Colorectal cancer; Gastric cancer; HER2 positive breast cancer; Oesophageal cancer
  • Phase II Gynaecological cancer
  • Phase I/II Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 28 May 2024 Jiangsu HengRui Medicine plans a phase III trial for Non-small cell lung cancer (First-line therapy, Late-stage disease, Metastatic disease) in China (IV) (NCT06430437)
  • 14 May 2024 Jiangsu HengRui Medicine plans a phase II trial for Biliary tract cancer (Late stage disease, Unresectable/Inoperable, Recurrent, Metastatic disease, Second-line therapy or greater) in China (IV)(NCT06413745)
  • 01 May 2024 Phase-II clinical trials in Breast cancer (Late-stage disease, Second-line therapy or greater, Combination therapy, Metastatic disease) in China (IV) (NCT06411457)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top